Treatment of Chronic Delta Hepatitis With Lonafarnib and Ritonavir

Trial Profile

Treatment of Chronic Delta Hepatitis With Lonafarnib and Ritonavir

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Oct 2017

At a glance

  • Drugs Lonafarnib (Primary) ; Ritonavir
  • Indications Hepatitis D
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms LOWR HDV - 3
  • Most Recent Events

    • 02 Oct 2017 According to an Eiger BioPharmaceuticals, Inc. media release, study and mathematical modeling designed to inform next steps in clinical development will be presented at the American Association for the Study of Liver Diseases (AASLD) 2017.
    • 21 Apr 2017 According to an Eiger BioPharmaceuticals, Inc. media release, data from the study has been presented at the The International Liver Congress 2017.
    • 21 Apr 2017 Results from the LOWER HDV program published in an Eiger BioPharmaceuticals, Inc. media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top